UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): December 8, 2015

Kite Pharma, Inc.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (310) 824-9999

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Item 8.01 Other Events.

Updated Company Disclosure

On December 8, 2015, Kite Pharma, Inc. (“Kite”) filed with the Securities and Exchange Commission (the “SEC”) a preliminary prospectus supplement pursuant to Rule 424(b)(5) under the Securities Act of 1933 (the “Preliminary Prospectus Supplement”), relating to a proposed public offering of shares of Kite’s common stock (the “Public Offering”). The Preliminary Prospectus Supplement for the Public Offering contains updated company risk factor disclosure as well as an updated description of certain aspects of Kite’s business. Accordingly, Kite is filing information for the purpose of supplementing and updating the risk factor disclosure contained in Kite’s prior public filings, including those discussed under the heading “Item 1A. Risk Factors” in Kite’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed with the SEC on November 12, 2015. Kite is also updating certain aspects of the description of Kite’s business from that described under the heading, “Item 1. Business” in Kite’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 26, 2015. The updated disclosures are filed herewith as Exhibit 99.1 and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

The following exhibit is filed as part of this Current Report:

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX